Chemotherapy in soft tissue sarcoma
The Scandinavian Sarcoma Group experience

References

• Alvegird T A, Sigurdsson H, Mouridsen H, Solheim 0, Unsgaard B, Ringborg U, Dahl 0, Nordentoft A M, Blomqvist C, Rydholm A, Stener B, Ranstam J. Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma Group. J Clin Oncol 1989; 7 (10): 1504–13.
   Google Scholar
• Antman K H. Chemotherapy of advanced sarcomas of bone and soft tissue. Sem in Oncol 1992; 19 (6) Suppl 12: 13–22.
   Google Scholar
• Antman K H, Ryan L, Elias A, Sherman D, Grier H E. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma, J Clin Oncol 1989; 7 (1): 126–31.
   Google Scholar
• Baker L H, Frank J, Fine G, Balcerzak S P, Stephens R L, Stuckey W J, Rivkin S, Saiki J, Ward J H. Combination chemotherapy using adriamycin, DTIC, cyclophos-phamide, and actinomycin D for advanced soft tissue sarcomas: a randomized comparative trial. A phase III, Southwest Oncology Group Study (7613). J Clin Oncol 1987; 5(6): 851–61.
   Google Scholar
• Balcerzak S P, Benedetti J, Weiss G R, Natale R B. A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas. Cancer 1995; 76(11): 2248–52.
   Google Scholar
• Benjamin R S. Should patients with advanced sarcomas be treated with chemotherapy? Pro. Eur J Cancer 1998; 34 (7): 958–62.
   PubMedGoogle Scholar
• Benjamin R S, Wiernik PH, Bachur N R. Adriamycin: a new effective agent in the treatment of disseminated sarcoma. Med Pediatr Oncol 1975; 1(1): 63–76.
   Google Scholar
• Blay J Y, van Glabbeke M, Verweij J, van Oosterom A T, Le Cesne A, Oosterhuis J W, Judson I, Nielsen 0 S. Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer 2003; 39 (1): 64–9.
   Google Scholar
• Blum R H, Carter S K. Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med 1974; 80 (2): 249–59.
   Google Scholar
• Blum R. An overview of studies with adriamycin (NSC-123127) in the United States. Cancer Chemother Rep Part 3 1975; 6(2): 247–51.
   Google Scholar
• Blum R H, Edmonson J, Ryan L, Pelletier L. Efficacy of ifosfamide in combination with doxorubicin for the treatment of metastatic soft-tissue sarcoma. The Eastern Cooperative Study Group. Cancer Chemother Pharmacol 1993; 31 (suppl 2): 238–40.
   Google Scholar
• Bokemeyer C, Franzke A, Hartmann J T, Schober C, Arse-niev L, Metzner B, Link H, Kanz L, Schmoll H J. A phase VII study of sequential, dose-escalated, high dose ifos-famide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. Cancer 1997; 80 (7): 1221–7.
   Google Scholar
• Borden E C, Amato D A, Rosenbaum C, Enterline H T, Shiraki M J, Creech R H, Lerner H J, Carbone P P. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 1987; 5 (6): 840–50.
   PubMedGoogle Scholar
• Borden E C, Baker L H, Bell R S, Bramwell V, Demetri GD, Eisenberg B L, Fletcher C D, Fletcher J A, LadanyiM, Meltzer P, O'Sullivan B, Parkinson D R, Pisters P W, Saxman S, Singer S, Sundaram M, van Oosterom AT, Verweij J, Waalen J, Weiss SW, Brennan ME Soft tissue sarcomas in adults: state of the translational science. Clin Cancer Res 2003; 9 (6): 1941–56.
   PubMedGoogle Scholar
• Bramwell V H C. Chemotherapy for metastatic soft tissue sarcoma - another full circle? Br J Cancer 1991; 64 (1): 7–9.
   PubMedGoogle Scholar
• Bramwell V H C, Eisenhauer E A, Blacksten M, Boos G, Knowling M, Jolivet J, Bogues W. Phase II study of topo-tecan (NSC 609 699) in patients with recurrent or meta-static soft tissue sarcoma. Ann Oncol 1995; 6 (8): 847–9.
   PubMedGoogle Scholar
• Connelly E F, Budd G T. Ifosfamide in the treatment of soft tissue sarcoma. Seminars in oncology 1996; 23 (3) Suppl 6: 16–21.
   Google Scholar
• Creagan E T, Hahn R G, Ahmann D L, Bisel HE A clinical trial of Adriamycin (NSC-123127) in advanced sarcomas. Oncology 1977; 34(2): 90–1.
   PubMedGoogle Scholar
• Demetri G D, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts P J, Heinrich M C, Tuveson
   Google Scholar
• D A, Singer S, Janicek M, Fletcher J A, Silverman S G, Silberman S L, Capdeville R, Kiese B, Peng B, Dimitri-jevic S, Druker B J, Corless C, Fletcher C D, Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347 (7): 472–80.
   Google Scholar
• Dumontet C, Biron P, Bouffet E, Blay J Y, Meckenstock R, Chauvin F, Philip I, Clavel M, Brunat-Mentigny M, Philip T. High dose chemotherapy with ABMT in soft tissue sar-comas: a report of 22 cases. Bone Marrow Transpl 1992; 10(5): 405–8.
   Google Scholar
• Edmonson J H, Ryan L M, Blum R H, Brooks J S J, Shiraki M, Frytak S, Parkinson D R. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against soft tissue sarcomas. J Clin Oncol 1993; 11(7): 1269–75.
   PubMedGoogle Scholar
• Elias A, Ryan L, Sulkes A, Collins J, Aisner J, Antman K J. Response to mesna, doxorubicin, ifosfamide and dacar-bazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol 1989; 7 (9): 1208–16.
   Google Scholar
• Enzinger F M, Weiss S W. General considerations. In: Soft tissue tumors. (Ed. Enzinger FM and Weiss SW). Mosby. St Louis 1988: 1–18.
   Google Scholar
• Frustaci S, Buonadonna A, Galligioni E, Favaro D, De Paoli A, Lo Re G, Sorio R, Tumolo S, Monfardini S. Increasing 4'-epidoxorubicin and fixed ifosfamide doses plus granu-locyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a pilot study. J Clin Oncol 1997; Apr;15 (4): 1418–26.
   Google Scholar
• Frustaci S, Gherlinzoni F, De Paoli A, Bonetti M, Azzarelli A, Comandone A, Olmi P, Buonadonna A, Pignatti G, Barbieri E, Apice G, Zmerly H, Serraino D, Picci P. Adju-vant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 2001; 19(5): 1238–47.
   PubMed Web of Science ®Google Scholar
• Frustaci S, De Paoli A, Bidoli E, La Mura N, Berretta M, Buonadonna A, Boz G, Gherlinzoni E Ifosfamide in the adjuvant therapy of soft tissue sarcomas. Oncology 2003; 65 (Suppl 2): 80–4.
   PubMed Web of Science ®Google Scholar
• Fletcher C D, Berman J J, Corless C, Gorstein F, Lasota J, Longley B J, Miettinen M, O'Leary T J, Remotti H, RubinB P, Shmoolder B, Sobin L H, Weiss S W. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol. 2002; 33 (5): 459–65.
   Google Scholar
• Gadd M A, Casper E S, Woodruff J M, McCormack P M, Brennan M E Development and treatment of pulmonary metastases in adult patients with extremity soft tissue sar-coma. Annals of Surgery 1993; 218 (6): 705–12.
   PubMedGoogle Scholar
• Gottlieb J A, Baker L H, O'Bryan R M, Sinkovics J G, Hoogstraten B, Quangliana J M, Rivkin S E, Bodey G P Sr, Rodrigues VT, Blumenschein G R, Saiki J H, ColtmanC Jr, Burgess MA, Sullivan P, Thigpen T, Bottomley R, Balcerzak S, Moon T E. Adriamycin (NSC 123127) used alone or in combination. Cancer Chemother Rep Part 3 1975; 6(2): 271–82.
   Google Scholar
• Gustafson P. Soft tissue sarcoma. Epidemiology and prog-nosis in 508 patients. Acta Orthop Scand 1994; 65 (suppl 259): 1–31.
   Google Scholar
• Gustafson P, Akerman M, Alvegird T A, Coindre J M, Fletcher CD, Rydholm A, Willen H. Prognostic informa-tion in soft tissue sarcoma using tumour size, vascular invasion and microscopic tumour necrosis-the SIN-system. Eur J Cancer 2003; 39(11): 1568–76.
   Google Scholar
• Heinrich M C, Corless C L, Demetri G D, Blanke C D, von Mehren M, Joensuu H, McGreevey L S, Chen C J, Van den Abbeele AD, Druker B J, Kiese B, Eisenberg B, Rob-erts P J, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher J A. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21(23): 4342–9.
   Google Scholar
• Helman L J, Meltzer P. Mechanisms of sarcoma develop-ment. Nat Rev Cancer 2003; 3 (9): 685–94.
   PubMedGoogle Scholar
• Hensley M L, Maki R, Venkatraman E, Geller G, Loveg-ren M, Aghajanian C, Sabbatini P, Tong W, Barakat R, Spriggs D R.Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002; 20(12): 2824–31.
   Google Scholar
• Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tullio G, Matsuzawa Y, Kanakura Y, Shino-mura Y, Kitamura Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279 (5350): 577–80.
   Google Scholar
• Jaques D P, Coit D G, Casper E S, Brennan M E Hepatic metastases from soft-tissue sarcoma. Ann Surg 1995; 221 (4): 392–7.
   PubMedGoogle Scholar
• Joensuu H, Roberts P J, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, CapdevilleR, Dimitrijevic S, Druker B, Demetri G D. Effect of the tyrosine kinase inhibitor STI571 in a patient with a meta-static gastrointestinal stromal tumor. N Engl J Med 2001; 344 (14): 1052–6.
   Google Scholar
• Kindblom L G, Remota H E, Aldenborg F, Meis-Kindblom J M. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic charac-teristics of the interstitial cells of Cajal. Am J Pathol 1998; 152 (5): 1259–69.
   Google Scholar
• Kindblom L G, Meis-Kindblom J, Bliimming P, DimitrijevicS, Miret M, Dortok A et al. Incidence, prevalence, pheno-type and biologic spectrum of gastrointestinal stromal cell tumors (GIST) — a population based study of 600 cases. Ann Oncol 2002; 13 suppl 5: abstract 5770.
   Google Scholar
• Le Cesne A, Antoine E, Spielmann M, Le Chevalier T, Brain E, Toussaint C, Janin N, Kayitalire L, Fontaine F, Genin J, Vanel D, Contesso G, Tursz T. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Chin Oncol 1995; 13 (7): 1600–8.
   Google Scholar
• Le Cesne A, Judson I, Crowther D, Rodenhuis S, Keizer H J, Van Hoesel Q, Blay J Y, Frisch J, Van Glabbeke M, Her-mans C, Van Oosterom A, Tursz T, Verweij J. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifos-famide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarco-mas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000; 18 (14): 2676–84.
   Google Scholar
• Levine E A, Holzmayer T, Bacus S, Mechetner E, Mera R, Bolliger C, Roninson I B, Das Gupta T K. Evaluation of newer prognostic markers for adult soft tissue sarcomas. J Clin Oncol 1997; 15 (10): 3249–57.
   Google Scholar
• Nielsen 0 S, Dombernowsky P, Mouridsen H, Crowther D, Verweij J, Buesa J, Steward W, Daugaard S, van Glabbeke
   Google Scholar
• M, Kirkpatrick A, Tursz T.High-dose epirubicin isnot an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group. Br J Cancer 1998; 78 (12): 1634–9.
   Google Scholar
• O'Bryan R M, Baker L H, Gottlieb J B, Rivkin S E, Bal-cerzak S P, Grumet G N, Salmon S E, Moon T E, Hoog-straten B. Dose response evaluation of Adriamycin in human neoplasia. Cancer 1977; 39 (5): 1940–8.
   PubMedGoogle Scholar
• O'Bryan R M, Luce J K, Talley, R W, Gottlieb J A, Baker LH, Bonadonna G. Phase II evaluation of Adriamycin in human neoplasia. Cancer 1973; 32 (1): 1–8.
   PubMedGoogle Scholar
• Okuno S, Ryan L M, Edmonson J H, Priebat D A, Blum R H. Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): a trial of the Eastern Cooperative Oncology Group. Cancer 2003; 97 (8): 1969–73.
   PubMed Web of Science ®Google Scholar
• Patel S R, Vadhan-Raj S, Papadopolous N, Plager C, Bur-gess MA, Hays C, Benjamin R S. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies - dose-response and schedule dependence. J Chin Oncol 1997; 15 (6): 2378–84.
   PubMedGoogle Scholar
• Pinedo H M, Bramwell V H C, Mouridsen M D, Somers R, Vendrik C P J, Santoro A, Buesa J, Wagener T H, van Oosterom AT, van Unnik J AM, Sylvester R, De Pauw M, Thomas D, Bonadonna G. Cyvadic in advanced soft tissue sarcoma: a randomized study comparing two schedules. A study of the EORTC Soft Tissue and Bone Sarcoma Group. Cancer 1984; 53 (9): 1825–32.
   Google Scholar
• Putnam J B Jr, Roth J A, Wesley MN, Johnston M R, Rosen-berg S A. Analysis of prognostic factors in patients under-going resection of pulmonary metastases from soft tissue sarcomas. J Thorac Cardiovasc Surg 1984; 87 (2): 260–8.
   PubMedGoogle Scholar
• Reichardt, P. Should high-dose chemotherapy be used in the treatment of soft tissue sarcoma?: Pro. Eur J Cancer 1997; 33 (9): 1351–4.
   PubMed Web of Science ®Google Scholar
• Reichardt P, Tilgner J, Hohenberger P, Dorken B. Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study. J Clin Oncol 1998; Apr;16 (4): 1438–43.
   PubMedGoogle Scholar
• Rouesse J, Bourgeois H. Should patients with advanced sarcomas be treated with chemotherapy?: Contra. Eur J Cancer 1998; 34 (7): 962–4.
   Web of Science ®Google Scholar
• Saeter G, Alvegird TA, Monge 0 R, Strander H, TuressonI, Klepp R, Soderberg M, Wist E, Raabe N, Erlanson M, Solheim 0 P, Hannisdal E. Ifosfamide and continuous infusion Etoposide in advanced adult soft tissue sarcoma. A Scandinavian Sarcoma Group phase II study. Eur J Cancer 1997; 33 (10): 1551–8.
   Google Scholar
• Saeter G, Talle K, Solheim 0 P. Treatment of advanced, high-grade soft-tissue sarcoma with ifosfamide and continous-infusion etoposide. Cancer Chemotherapy and Pharmacology 1995; 36: 172–5.
   Google Scholar
• Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R, Buesa J, Casali P, Spooner D, Rankin E, Kirk-patrick A, van Glabbeke M, van Oosterom A. Doxorubi-cin versus CYVADIC versus Doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995; 13 (7): 1537–45.
   Google Scholar
• Schmidt R A, Conrad ifi E U, Collins C, Rabinovitch P, Finney A. Measurement and prediction of the short-term response of soft tissue sarcoma to Chemotherapy. Cancer 1993; 72(9): 2593–601.
   PubMedGoogle Scholar
• Schoenfeld D A, Rosenbaum C, Horton J, Wolter J M, Falk-son G, DeConti R C. A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide for advanced sarcoma. Cancer 1982; 50 (12): 2757–62.
   Google Scholar
• Singer S, Corson J M, Demetri G D, Healey E A, Marcus K, Eberlein T J. Prognostic factors predictive of survival for truncal and retroperitoneal soft-tissue sarcoma. Ann Surg 1995; 221 (2): 185–95.
   PubMed Web of Science ®Google Scholar
• Skapek S X, Shaffer L G, Barker J A. Cytogenetics and the biological basis of sarcomas. Current Opinion in Oncol 1998; 10 (4): 318–25.
   PubMedGoogle Scholar
• Steward W P, Verweij J, Somers R, Spooner D, Kerbrat P, Clavel M, Crowther D, Rouesse J, Tursz T, Tueni E, Van Oosterom A T, Warwick J, Greifenberg B, Thomas D, van Glabbeke M. Granulocyte-macrophage colony-stimulat-ing factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1993; 11(1): 15–21.
   Google Scholar
• Stuart-Harris R, Harper P G, Kaye S B, Wiltshaw E. High-dose ifosfamide by infusion with mesna in advanced soft tissue sarcoma. Cancer Treat Rev 1983; 10 (suppl A): 163–4.
   Google Scholar
• Tierney J F, Stewart LA, Parmar, M K B. Adjuvant che-motherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet 1997; 350: 1647–54.
   Google Scholar
• Van Geel A N, Pastorino U, Jauch K W, Judson I R, van Coevorden F, Buesa J M, Nielsen 0 S, Boudinet A, Tursz T, Schmitz P I M. Surgical treatment of lung metastases. Cancer 1996; 77 (4): 675–82.
   Google Scholar
• Van Glabbeke M, van Oosterom AT, Oosterhuis J W, Mou-ridsen H, Crowther D, Somers R, Verweij J, Santoro A, Buesa J, Tursz T. Prognostic factors in advanced soft tissue sarcoma (STS): an overview of 1742 patients treated with doxorubicin containing first line regimens by the EORTC Soft Tissue and Bone Sarcoma Group (STBSG). Annals of Oncol 1994; 5 (suppl 8): 171.
   Google Scholar
• Van Glabbeke M, van Oosterom AT, Oosterhuis J W, Mou-ridsen H, Crowther D, Somers R, Verweij J, Santoro A, Buesa J, Tursz T. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analy-sis of 2,185 patients treated with anthracycline-contain-ing first-line regimens —a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 1999; 17(1): 150–7.
   Google Scholar
• Van Glabbeke M, Verweij J, Judson I, Nielsen OS; EORTC Soft Tissue and Bone Sarcoma Group Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer. 2002; 38 (4): 543–9.
   PubMed Web of Science ®Google Scholar
• van-Haelst-Pisani C M, Buckner J C, Reiman H M, Schaid D J, Edmonson J H, Hahn R G. Does histologic grade in soft tissue sarcoma influence response rate to systemic chemotherapy? Cancer 1991; 68 (11): 2354–8.
   Google Scholar
• van Hoesel 0 G CM, Verweij J, Catimel G, Clavel M, Kerbat P, van Oosterom AT, Kerger J, Tursz T, van Glabbeke M, van Pottelsberghe C, le Bail N, Mouridsen H. Phase II study with docetaxel (Taxotere®) in advanced soft tissue sarcomas of the adult. Ann Oncol 1994; 5 (6): 539–42.
   Google Scholar
• Verweij J, van Oosterom a, Blay J Y, Judson I, Rodenhus S, van der Graaf W, Radford J, Le Cesne A, Hogendoorn P C, di Paola E D, Brown M, Nielsen 0 S. Imatinib mesylate (STI-571 Glivec, Gleevec) is and active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003; 39(14); 2006–11.
   Google Scholar
• Weitz J, Antonescu C R, Brennan M E Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival overtime. J Clin Oncol 2003; 21(14): 2719–25.
   PubMed Web of Science ®Google Scholar
• Weisberg E, Griffin J D. Resistance to imatinib (Glivec): update on clinical mechanisms. Drug Resist Updat 2003; 6 (5): 231–8.
   PubMedGoogle Scholar
• Verweij J, van Oosterom A, Blay J Y, Judson I, Rodenhuis S, van der Graaf W, Radford J, Le Cesne A, Hogendoorn P C, di Paola E D, Brown M, Nielsen 0 S. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003; 39(14): 2006–11.
   Google Scholar
• Wiklund T A, Blomqvist C, Virolainen M, Elomaa I. Ifosfamide, vincristine, doxorubicin and dacarbazine (IVADIC) in patients with advanced soft tissue sarcoma. Cancer Chemother Pharmacol 1992; 30: 100–4.
   PubMedGoogle Scholar
• Wiklund T, Saeter G, Strander H, Alvegird T, Blomqvist C. The outcome of advanced soft tissue sarcoma patients with complete tumour regression after either chemo-therapy alone or chemotherapy plus surgery. The Scan-dinavian Sarcoma Group experience. Eur J Cancer 1997; 33 (3): 357–61.
   Google Scholar